YHO-13351
Code | Size | Price |
---|
TAR-T13366-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T13366-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific BCRP inhibitor.
CAS:
1346753-00-1
Formula:
C27H37N3O7S2
Molecular Weight:
579.73
Pathway:
Chromatin/Epigenetic
Purity:
0.98
SMILES:
CS(O)(=O)=O.CCN(CC)CC(=O)OC1CCN(CC1)c1ccc(C=C(/C#N)c2ccc(OC)c(OC)c2)s1
Target:
Epigenetic Reader Domain
References
1. Yamazaki R, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011 Jul;10(7):1252-63.